Physician profile
Mark V Jarowenko
NPI 1285666347
$1,994.81
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $113 · 2021: $670 · 2022: $606 · 2023: $29.65 · 2024: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $455.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $442.42 | 2020-2022 | |
| Urovant Sciences INC | $341.62 | 2021-2022 | |
| Procept Biorobotics Corporation | $147.16 | 2024 | Aquabeam System |
| Boston Scientific Corporation | $143.70 | 2019-2022 | |
| Neotract INC. | $91.44 | 2019 | |
| Olympus America INC. | $35.88 | 2021-2022 | |
| Coloplast Corp | $33.64 | 2022 | |
| Merck Sharp & Dohme LLC | $31.42 | 2021-2022 | |
| Travere Therapeutics, INC. | $31.32 | 2019-2020 | |
| Abbvie INC. | $29.65 | 2023 | |
| Blue Earth Diagnostics | $28.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.06 | 2022 | |
| Janssen Biotech, INC. | $25.82 | 2019 | |
| Dendreon Pharmaceuticals LLC | $21.94 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $20.03 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.65 | 2019 | |
| Axonics, INC. | $17.07 | 2021 | |
| Accord Healthcare, INC. | $14.49 | 2022 | |
| Pfizer INC. | $13.89 | 2021 | |
| Myovant Sciences INC. | $12.49 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.38 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$986.22 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jarowenko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.